CASE REPORT

Two patients with premature labour associated with *Mycoplasma hominis* infection

M. SHIMADA, T. KOTANI, H. SAMESHIMA*, Y. NAGAMINE*, Y. KODAMA*, T. IKENOUE*, T. KENRI†, T. SASAKI† and S. OHTAKI

Central Laboratory for Clinical Investigation and *Department of Obstetrics and Gynecology, Miyazaki Medical College Hospital, Kihara 5,200, Kiyotake, Miyazaki 889-16 and †Department of Safety Research on Biologics, National Institute of Health, Gakuen 4-7-1, Musashimurayama, Tokyo 208, Japan

Because several reports have suggested that bacterial vaginosis causes premature labour and early rupture of the fetal membranes, the presence of a bacterial flora that causes bacterial vaginosis is thought to be a risk factor for premature labour. The present study investigated two patients with premature delivery and intra-uterine *Mycoplasma hominis* infection. In microbiological studies, Gram's staining of amniotic fluids revealed numerous neutrophils and epithelial cells but no micro-organisms. Culture of amniotic fluid before antibiotic therapy yielded only *M. hominis* under anaerobic conditions; aerobic culture was negative. Vaginal discharge taken on the day of delivery yielded no growth in case 1 and *M. hominis* and *Enterococcus faecalis* in case 2. Maternal sera showed specific antibodies to *M. hominis* by ELISA and immunoblotting. As no possible cause of premature labour other than *M. hominis* infection was detected, it is concluded that the intra-uterine *M. hominis* infection was associated with premature labour in these patients.

Introduction

*Mycoplasma hominis* is isolated frequently from the human genital tract. It has been suggested that *M. hominis* can cause pelvic inflammatory disease [1], sepsis, wound infection, etc. [2]. Recent reports have suggested that women with bacterial vaginosis and vaginal gram-negative anaerobes and *M. hominis* are at the highest risk for the premature delivery of low birth weight infants [3]. This study describes two cases in which *M. hominis* infection was thought to cause premature labour. The clinical courses and laboratory findings in these cases are reported.

Patients and methods

Case 1

A 26-year-old woman was admitted to this hospital on 20 Aug. 1992 because of premature labour due to intrauterine infection. This was her first planned pregnancy and gestation was 26 weeks. The body temperature was 38°C, leucocyte count was 24,000/µl and C-reactive protein was 4 mg/dl. She delivered the baby several hours after admission. The baby exhibited no signs of clinical illness. Apgar scores at 1 and 5 min were 8 and 9, respectively. After delivery she was given 2 g of cefotiam per day for 4 days. Although cefotiam decreased her body temperature to 37°C, C-reactive protein of 3.5 mg/dl persisted. Culture of the white and slightly turbid amniotic fluid yielded *M. hominis*, but there was no growth of bacteria from vaginal discharge. Gram-staining of the amniotic fluid and vaginal discharge showed only white blood cells. Histological examination of placental sections with both haematoxylin and eosin and methylene blue staining revealed neutrophilic infiltration in the chorioamniotic plates and around the umbilical vein, but did not show bacteria.

Case 2

A 25-year-old woman with premature membrane rupture and suspicion of intra-uterine infection was admitted to this hospital on 16 April 1994. Gestation was 32 weeks. Her obstetric history was as follows: dilatation and curettage at 18 years, spontaneous abortion at 13 weeks of pregnancy at 22 years, and at 23 years a Caesarean section at 40 weeks of...
pregnancy for fetal distress. On admission, leucocyte count was 15,000/μl, C-reactive protein 2 mg/dl and body temperature 37.1°C. Four days after admission, a Caesarean section was performed at 32 weeks gestation for progressive fetal distress. Apgar scores at 1 and 5 min were 7 and 10, respectively. The baby showed no signs of clinical illness. Maternal leucocyte count and C-reactive protein after operation increased to 16,700/μl and 14.3 mg/dl, respectively. Cefotiam at 600 mg/day for 3 days was administered as empirical therapy. Culture of the amniotic fluids yielded *M. hominis*. Culture of vaginal discharge and cervical secretions obtained at Caesarean section yielded *M. hominis* and *Enterococcus faecalis*. Light microscopic examination showed many white blood cells and epithelial cells. On histological examination, similar findings to those in case 1 were observed.

**Patients’ sera**

Acute phase serum was taken from the maternal blood when *M. hominis* was isolated. Convalescent serum was collected 7 weeks after isolation of *M. hominis* in case 1, and 3 weeks after isolation in case 2. All sera were kept at −70°C until testing.

**Isolation and identification of M. hominis**

Amniotic fluids and cervicovaginal secretions were streaked on modified Gifu Anaerobic Medium (GAM) blood agar (Nissui Pharmaceutical Co. Ltd, Tokyo, Japan) for isolation of anaerobic bacteria, chocolate agar (Nissui Pharmaceutical Co. Ltd) for isolation of *Gardnerella vaginalis* and *Neisseria gonorrhoeae*, Trypticase Soy Agar II with sheep blood 5% (Nippon Becton Dickinson Co. Ltd, Tokyo, Japan) and BTB Lactose Agar (Eiken Chemical Co. Ltd, Tokyo, Japan) for isolation of aerobic bacteria, respectively. Modified GAM blood agar was incubated under anaerobic conditions (N2 80%, H2 10%, CO2 10%) for 7 days. Both trypticase soy agar II with sheep blood 5% and BTB lactose agar were incubated in aerobic conditions for 72 h. *M. hominis* was identified by the metabolic inhibition (MI) test [4] with specific rabbit antisera against *M. hominis*, *M. orale* and *M. salivarium*, respectively.

**Micro-organisms and growth conditions**

*M. hominis* PG21 was grown at 37°C in a broth medium consisting of PPLO Broth Base (Difco Laboratories, Detroit, MI, USA) 2.1% w/v, phenol red 0.01% w/v, and arginine monohydrochloride 0.25% w/v. The cells grown in 1 L of culture medium were centrifuged (16,000 g for 30 min) when the pH of the medium began to change. The pellets were washed twice by centrifugation and resuspended in 5 ml of PBS. The cell suspension was sonicated at 20,000 Hz for 3 min and used as the cell lysate.

**Measurement of antibodies against M. hominis, Chlamydia trachomatis and Ureaplasma urealyticum**

Antibodies to *M. hominis* were measured by enzyme-linked immunosorbent assay (ELISA) and the MI test. The ELISA was performed according to the procedures described by Sasaki et al. [5, 6]. An ELISA value of >0.15 was regarded as positive for *M. hominis* infection in the light of values from normal sera in this ELISA system. Antibody titres for *U. urealyticum* and *C. trachomatis* were assayed by the MI test and microimmunofluorescence technique, respectively.

**Immunoblotting**

Immunoblotting was performed according to the procedures described by Sasaki et al. [6].

**Estimation of protein concentration**

Protein concentrations were determined by the method of Lowry et al. [7] with bovine serum albumin as a standard.

**Results**

After incubation for 72 h, only modified GAM blood agar yielded microcolonies which glistened and were translucent in both cases. In the MI test, only anti-*M. hominis* serum inhibited the growth of the isolated micro-organisms. The above results showed that the micro-organisms from specimens of the patients were *M. hominis*. Acute phase and convalescent sera showed 0.025 and 0.410 ELISA values at A405 nm, respectively, in case 1. Similarly, in case 2, 0.489 and 0.772 ELISA values were obtained in paired sera. In further analysis by immunoblotting, convalescent sera from both cases showed some reactive bands that were not recognised in acute phase sera (Fig. 1). Maternal MI antibody titre to 14 serotypes of *U. urealyticum* were all <20. IgM antibody titre to *C. trachomatis* was also <10.

**Discussion**

There have been several reports suggesting that bacterial vaginosis influences the outcome of pregnancy in association with premature labour and premature rupture of the membranes. In a cohort study, Hillier et al. demonstrated that women with bacterial vaginosis and infection with *Bacteroides* spp. and *M. hominis* were at the highest risk of premature delivery of low birth weight infants [3], because bacterial vaginosis appears to predispose to an ascending infection of the chorioamnion and amniotic fluid and this subsequently leads to prematurity [3, 8].

As preterm infection of the chorioamnion appears to have many bacterial causes, it is difficult to assess the
role of any single organism in chorioamnionitis and prematurity [9]. However, we have encountered rare cases of preterm delivery with intra-uterine M. hominis infection. Only a few case reports on abortion due to M. hominis infection in the upper genitourinary tract have been described in the past [10–12]. Nevertheless, these patients had additional risk factors for spontaneous abortion. A rise in antibody titre against M. hominis was not recognised [10, 11] and the presence of another micro-organism which might have been the actual aetiological agent was not completely excluded [10, 12]. In the present cases, only M. hominis was isolated from their amniotic fluids collected by intra-abdominal amniocenteses before antibiotic administration, although the study did not attempt to isolate bacteria from chorion and amnion. Furthermore, the results of immunoblotting and ELISA corroborated M. hominis infection. As it has been reported that vaginal colonisation by lactobacilli in pregnant women appeared to protect against premature delivery [13], we considered that absence of vaginal lactobacilli contributed to an ascending intra-uterine infection by M. hominis. In case 2, acute phase serum showed a positive ELISA value for M. hominis infection. This result was thought to be due to the patient having chronic M. hominis infection before admission. Thus, it was speculated that intra-uterine M. hominis infection caused the premature labour in these two patients.

In a prospective study of the vaginal flora, G. vaginalis, U. urealyticum and M. hominis commonly persisted between midtrimester and labour, particularly in the preterm cohort. However, these organisms were rarely acquired late in pregnancy [14]. Furthermore, bacterial vaginosis is associated with an increased rate of second trimester miscarriage and premature delivery. These findings suggest that any treatment aimed at the eradication of these micro-organisms in pregnancy should not be given later than the beginning of the second trimester of pregnancy [15]. Metronidazole is effective but toxic, and it is not recommended for use in pregnant women. Because of efficacy and safety considerations, clindamycin (CLDM) is preferred to metronidazole for bacterial vaginosis [16]. However, McGregor et al. reported that local administration of CLDM to pregnant women with bacterial vaginosis was ineffective in reducing the incidence of premature labour, even though clinical efficacy was observed. Because local administration is hardly effective against bacteria which have invaded the uterus, they suggested systemic administration of CLDM [17]. Further study on the treatment of M. hominis infection is eagerly awaited.

References